# OnCo record hr-positive-metastatic-post-cdk46 (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hr-positive-metastatic-post-cdk46" ;
  schema:name "HR-positive metastatic breast cancer after CDK4/6 inhibitors"@en ;
  schema:alternateName "Endocrine-resistant metastatic breast cancer"@en, "ESR1-mutant breast cancer"@en, "PIK3CA-mutant breast cancer"@en, "AKT pathway-altered breast cancer"@en, "Second-line HR-positive metastatic breast cancer"@en ;
  schema:description "When hormone-positive breast cancer grows through a CDK4/6 inhibitor, a blood test picks the next drug. Tumours with an acquired ESR1 mutation respond to the oral degraders elacestrant, camizestrant and imlunestrant; tumours with PIK3CA, AKT1 or PTEN changes to capivasertib, inavolisib or alpelisib; and once endocrine options run out, antibody-drug conjugates come before chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Breast_cancer> ;
  schema:citation <https://doi.org/10.1200/JCO.22.00338>, <https://doi.org/10.1056/NEJMoa2214131>, <https://doi.org/10.1056/NEJMoa2404625>, <https://clinicaltrials.gov/study/NCT04964934> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/vepdegestrant/>, <https://onco.cc/drugs/gedatolisib/>, <https://onco.cc/drugs/giredestrant/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/trials/cambria/>, <https://onco.cc/trials/evera/>, <https://onco.cc/trials/pik3ca-2/>, <https://onco.cc/drugs/tersolisib/>, <https://onco.cc/drugs/atirmociclib/>, <https://onco.cc/drugs/samuraciclib/>, <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:standardOfCare <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/trials/emerald/>, <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/trials/ember-3/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/trials/serena-6/>, <https://onco.cc/drugs/vepdegestrant/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/trials/capitello-291/>, <https://onco.cc/drugs/alpelisib/>, <https://onco.cc/trials/solar-1/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/trials/inavo120/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/trials/postmonarch/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/exemestane/>, <https://onco.cc/trials/evera/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast06/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/trials/tropics-02/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/trials/tropion-breast01/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympiad/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/trials/embraca/>, <https://onco.cc/terms/gbrca-mutation/> .